NCT06333821 is a Phase 3 clinical trial of Nimotuzumab in Cervical Cancer, sponsored by Biotech Pharmaceutical Co., Ltd..

Who is sponsoring NCT06333821?

NCT06333821 is sponsored by Biotech Pharmaceutical Co., Ltd..

What drugs are being tested in NCT06333821?

Interventions in NCT06333821: Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab.

What condition does NCT06333821 study?

NCT06333821 studies Cervical Cancer.

Is NCT06333821 still recruiting?

NCT06333821 is currently not yet recruiting. Last updated 27 March 2024.

Last reviewed 2024-03-27 · How we verify

NCT06333821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruiting Phase 3 Last updated 27 March 2024

What this trial tests

Phase 3 trial testing Nimotuzumab in Cervical Cancer in 460 participants. Not yet recruiting.

Timeline

1 April 2024

Primary endpoint
1 April 2030

1 April 2030

Quick facts

Lead sponsor	Biotech Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	460
Start date	1 April 2024
Primary completion	1 April 2030
Estimated completion	1 April 2030

Drugs / interventions tested

Nimotuzumab — full drug profile →
Cisplatin (cisplatin) — full drug profile →
External Beam Radiotherapy (EBRT)
Brachytherapy — full drug profile →
placebo for Nimotuzumab — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Biotech Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 80, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma. The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.
Wei S, Li X, Liu Z, Wei L, et al · · 2026 · PMID 41514314 · DOI 10.3802/jgo.2026.37.e46

Verify or expand the search:

Other trials of Nimotuzumab

Trials testing the same drug.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Biotech Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07582822 — JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC · Phase 1 · not yet recruiting
NCT07510841 — JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR · Phase 1, PHASE2 · not yet recruiting
NCT06633055 — A Phase I Clinical Trial of JH013 Injection · Phase 1 · not yet recruiting
NCT05978050 — Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma · Phase 3 · recruiting
NCT05978544 — Safety and Preliminary Clinical Activity of Itolizumab in ARDS · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06333821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biotech Pharmaceutical Co., Ltd.
Last refreshed: 27 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06333821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing